Anti-transglutaminase immunoreactivity and histological lesions of the duodenum in coeliac patients.

Coeliac disease (CD) is characterized by several markers, including anti-transglutaminase auto-antibodies (tTGAb) directed against multiple epitopes of the gliadin protein. We aimed to investigate the correlation among CD duodenal lesions, tTGAb titres and the immunoreactivity against tTG constructs. A total of 345 CD patients (209 females, 136 males, overall median age: 7.3 years) were tested for full-length (fl) tTGAb with a fluid-phase radioimmunoassay. Out of the total, 231 patients were also tested for immunoreactivity against tTG fragments (F1: a.a. 227-687 and F2: a.a. 473-687). Patients were classified according to diffuse (D), patchy (P) or bulb (B) histological lesions. All sera were found fltTGAb positive. Patients with D, P and B lesions had a mean Ab index of 0.84±0.39, 0.57±0.39 and 0.45±0.24, respectively. Mean tTGAb titre varied between D and localized (P+B) patients (0.84±0.39 versus 0.52±0.34, P < 0.0001). Overall, 86.1% of patients were F1 auto-antibody (F1Ab) positive (D: 89%, P: 75%, B: 40%; D versus P+B: P = 0.004) and 49% of patients were F2 auto-antibody (F2Ab) positive (D: 53%, P: 19%, B: 10%; D versus P+B: P = 0.0006). Of the D patients 50.7% showed combined F1Ab-F2Ab (D versus P+B: P = 0.001), whereas 60% of B patients were negative for both F1Ab and F2Ab (B versus D: P < 0.0001). Coeliac-specific tTGAb immunoreactivity correlates with the grading and extension of histological duodenal lesions in CD patients at diagnosis. The immunoreactivity against single and combined tTG fragments is significantly higher in patients with D lesions. This is the first evidence of a distinct coeliac-specific immunoreactivity in patients with different duodenal involvement.

[1]  A. Florena,et al.  Correlation Between IgA Tissue Transglutaminase Antibody Ratio and Histological Finding in Celiac Disease , 2012, Journal of pediatric gastroenterology and nutrition.

[2]  R. Nenna,et al.  Duodenal Bulb in Celiac Adults: The “Whether Biopsying” Dilemma , 2012, Journal of clinical gastroenterology.

[3]  I. Korponay-Szabó,et al.  A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects , 2011, Proceedings of the National Academy of Sciences.

[4]  S. Riestra,et al.  Duodenal biopsy may be avoided when high transglutaminase antibody titers are present. , 2009, World journal of gastroenterology.

[5]  E. Bonifacio,et al.  A Report on the International Transglutaminase Autoantibody Workshop for Celiac Disease , 2009, The American Journal of Gastroenterology.

[6]  S. Scotta,et al.  Duodenal Bulb Biopsies in Celiac Disease: A Multicenter Study , 2008, Journal of pediatric gastroenterology and nutrition.

[7]  M. Mazzilli,et al.  HLA-DQB1*02 Dose Effect on RIA Anti-tissue Transglutaminase Autoantibody Levels and Clinicopathological Expressivity of Celiac Disease , 2008, Journal of pediatric gastroenterology and nutrition.

[8]  P. Hill,et al.  Coeliac disease: a biopsy is not always necessary for diagnosis , 2008, Alimentary pharmacology & therapeutics.

[9]  M. Kagnoff AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease. , 2006, Gastroenterology.

[10]  E. Seidman,et al.  Guideline for the Diagnosis and Treatment of Celiac Disease in Children : Recommendations of the North American Society for Pediatric Gastroenterology , Hepatology and Nutrition , 2004 .

[11]  M. Mazzilli,et al.  Patchy Villous Atrophy of the Duodenum in Childhood Celiac Disease , 2004, Journal of pediatric gastroenterology and nutrition.

[12]  J. Sanders,et al.  Epitopes recognised by tissue transglutaminase antibodies in coeliac disease. , 2004, Journal of autoimmunity.

[13]  G. Eisenbarth,et al.  Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent. , 2003, Clinical immunology.

[14]  R. Marzari,et al.  The analysis of the fine specificity of celiac disease antibodies using tissue transglutaminase fragments. , 2002, European journal of biochemistry.

[15]  P. Steinert,et al.  Transglutaminases in disease , 2002, Neurochemistry International.

[16]  W. Scherbaum,et al.  Autoantibodies from patients with coeliac disease recognize distinct functional domains of the autoantigen tissue transglutaminase , 2001, Clinical and experimental immunology.

[17]  M. Greco,et al.  Radioimmunoassay to detect antitransglutaminase autoantibodies is the most sensitive and specific screening method for celiac disease , 2001, American Journal of Gastroenterology.

[18]  G. Oberhuber,et al.  Diagnostic duodenal bulb biopsy in celiac disease. , 2001, Endoscopy.

[19]  G. Oberhuber,et al.  The histopathology of coeliac disease: time for a standardized report scheme for pathologists. , 1999, European journal of gastroenterology & hepatology.

[20]  R. Casadio,et al.  The structural basis for the regulation of tissue transglutaminase by calcium ions. , 1999, European journal of biochemistry.

[21]  L. Fugger,et al.  Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease , 1998, Nature Medicine.

[22]  D. Schuppan,et al.  Identification of tissue transglutaminase as the autoantigen of celiac disease , 1997, Nature Medicine.

[23]  R. Graham,et al.  Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. , 1994, Science.